Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Pharmacokinetics of CAMPATH-1H in BMT patients.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
RILUTEK®
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Arzerra
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Cyclophosphamide
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Pages